Literature DB >> 16135753

Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.

Han Seok Ko1, Rainer von Coelln, Sathya R Sriram, Seong Who Kim, Kenny K K Chung, Olga Pletnikova, Juan Troncoso, Brett Johnson, Roya Saffary, Eyleen L Goh, Hongjun Song, Bum-Joon Park, Min Jung Kim, Sunghoon Kim, Valina L Dawson, Ted M Dawson.   

Abstract

Autosomal-recessive juvenile parkinsonism (AR-JP) is caused by loss-of-function mutations of the parkin gene. Parkin, a RING-type E3 ubiquitin ligase, is responsible for the ubiquitination and degradation of substrate proteins that are important in the survival of dopamine neurons in Parkinson's disease (PD). Accordingly, the abnormal accumulation of neurotoxic parkin substrates attributable to loss of parkin function may be the cause of neurodegeneration in parkin-related parkinsonism. We evaluated the known parkin substrates identified to date in parkin null mice to determine whether the absence of parkin results in accumulation of these substrates. Here we show that only the aminoacyl-tRNA synthetase cofactor p38 is upregulated in the ventral midbrain/hindbrain of both young and old parkin null mice. Consistent with upregulation in parkin knock-out mice, brains of AR-JP and idiopathic PD and diffuse Lewy body disease also exhibit increased level of p38. In addition, p38 interacts with parkin and parkin ubiquitinates and targets p38 for degradation. Furthermore, overexpression of p38 induces cell death that increases with tumor necrosis factor-alpha treatment and parkin blocks the pro-cell death effect of p38, whereas the R42P, familial-linked mutant of parkin, fails to rescue cell death. We further show that adenovirus-mediated overexpression of p38 in the substantia nigra in mice leads to loss of dopaminergic neurons. Together, our study represents a major advance in our understanding of parkin function, because it clearly identifies p38 as an important authentic pathophysiologic substrate of parkin. Moreover, these results have important implications for understanding the molecular mechanisms of neurodegeneration in PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135753      PMCID: PMC6725452          DOI: 10.1523/JNEUROSCI.2172-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

1.  Association between early-onset Parkinson's disease and mutations in the parkin gene.

Authors:  C B Lücking; A Dürr; V Bonifati; J Vaughan; G De Michele; T Gasser; B S Harhangi; G Meco; P Denèfle; N W Wood; Y Agid; A Brice
Journal:  N Engl J Med       Date:  2000-05-25       Impact factor: 91.245

2.  An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin.

Authors:  Y Imai; M Soda; H Inoue; N Hattori; Y Mizuno; R Takahashi
Journal:  Cell       Date:  2001-06-29       Impact factor: 41.582

3.  Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.

Authors:  H Shimura; M G Schlossmacher; N Hattori; M P Frosch; A Trockenbacher; R Schneider; Y Mizuno; K S Kosik; D J Selkoe
Journal:  Science       Date:  2001-06-28       Impact factor: 47.728

4.  Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.

Authors:  John F Staropoli; Caroline McDermott; Cécile Martinat; Brenda Schulman; Elena Demireva; Asa Abeliovich
Journal:  Neuron       Date:  2003-03-06       Impact factor: 17.173

5.  Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.

Authors:  K K Chung; Y Zhang; K L Lim; Y Tanaka; H Huang; J Gao; C A Ross; V L Dawson; T M Dawson
Journal:  Nat Med       Date:  2001-10       Impact factor: 53.440

6.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.

Authors:  H Shimura; N Hattori; S i Kubo; Y Mizuno; S Asakawa; S Minoshima; N Shimizu; K Iwai; T Chiba; K Tanaka; T Suzuki
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

7.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1.

Authors:  Y Zhang; J Gao; K K Chung; H Huang; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.

Authors:  Vincenzo Bonifati; Patrizia Rizzu; Marijke J van Baren; Onno Schaap; Guido J Breedveld; Elmar Krieger; Marieke C J Dekker; Ferdinando Squitieri; Pablo Ibanez; Marijke Joosse; Jeroen W van Dongen; Nicola Vanacore; John C van Swieten; Alexis Brice; Giuseppe Meco; Cornelia M van Duijn; Ben A Oostra; Peter Heutink
Journal:  Science       Date:  2002-11-21       Impact factor: 47.728

9.  CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity.

Authors:  Yuzuru Imai; Mariko Soda; Shigetsugu Hatakeyama; Takumi Akagi; Tsutomu Hashikawa; Kei Ichi Nakayama; Ryosuke Takahashi
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

10.  p38 is essential for the assembly and stability of macromolecular tRNA synthetase complex: implications for its physiological significance.

Authors:  Jin Young Kim; Young-Sun Kang; Joong-Won Lee; Hyoung June Kim; Young Ha Ahn; Heonyong Park; Young-Gyu Ko; Sunghoon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

View more
  100 in total

Review 1.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

Review 2.  Regulation of Parkin E3 ubiquitin ligase activity.

Authors:  Helen Walden; R Julio Martinez-Torres
Journal:  Cell Mol Life Sci       Date:  2012-04-19       Impact factor: 9.261

Review 3.  Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping.

Authors:  Sunghoon Kim; Sungyong You; Daehee Hwang
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

4.  Parkin mono-ubiquitinates Bcl-2 and regulates autophagy.

Authors:  Dong Chen; Feng Gao; Bin Li; Hongfeng Wang; Yuxia Xu; Cuiqing Zhu; Guanghui Wang
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

Review 5.  Parkin plays a role in sporadic Parkinson's disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

6.  Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease.

Authors:  Saurav Brahmachari; Saebom Lee; Sangjune Kim; Changqing Yuan; Senthilkumar S Karuppagounder; Preston Ge; Rosa Shi; Esther J Kim; Alex Liu; Donghoon Kim; Stephan Quintin; Haisong Jiang; Manoj Kumar; Seung Pil Yun; Tae-In Kam; Xiaobo Mao; Yunjong Lee; Deborah A Swing; Lino Tessarollo; Han Seok Ko; Valina L Dawson; Ted M Dawson
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

7.  JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress.

Authors:  Juhong Liu; Hye-Jung Chung; Matthew Vogt; Yetao Jin; Daniela Malide; Liusheng He; Miroslav Dundr; David Levens
Journal:  EMBO J       Date:  2011-02-01       Impact factor: 11.598

Review 8.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

9.  Identification and characterization of a novel endogenous murine parkin mutation.

Authors:  Chenere P Ramsey; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

10.  Manganese-induced toxicity in normal and human B lymphocyte cell lines containing a homozygous mutation in parkin.

Authors:  Jerome A Roth; Balakrishnan Ganapathy; Andrew J Ghio
Journal:  Toxicol In Vitro       Date:  2012-07-26       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.